BPC-157 was administered at doses of 10 g/kg, 1 g/kg, 100 ng/kg, and 10 ng/kg throughout the experiment, starting on day zero when therapy began, and daily during the trial periods of 7, 14, 21, 28, and 42 days
Dosing examples and conversions in this post reference Olympia Pharmaceuticals compounded Sermorelin Acetate 0.9 mg/mL liquid injection only, and should not be used in reference to sermorelin prepared or compounded by other facilities
Maeder ML, Stefanidakis M, Wilson CJ, Baral R, Barrera LA, Bounoutas GS, et al
BPC-157 sets up a favorable healing environment by raising growth factor levels, improving blood flow, and protecting existing tissue
The code captures the technical aspect of drug administration which is crucial for billing and reimbursement purposes
In the context of autoimmune disease, Thymalin's ability to support proper thymic selection, the very process whose failure leads to autoimmune disease, makes it a theoretical upstream intervention